Abstract | BACKGROUND: METHODS: We screened patients diagnosed and treated for CU and selected those that had symptoms despite antihistamine treatment. In a double-blind crossover study, patients took the leukotriene antagonist montelukast (10 mg per day) or placebo. Efficacy was assessed by a symptom score. RESULTS: In a group of 22 patients, the symptom score was not significantly different between periods using montelukast (48.8; 0-214) or placebo (68.5; 0-230). However in the subgroup of five patients with the most severe urticaria, defined as patients with symptom scores in the upper quartile at inclusion in the study, montelukast (41; 11 214) was superior to placebo (95.5; 48 230; p < 0.05), but only when using an in-house symptom score questionnaire and not when using a validated urticaria activity score questionnaire. CONCLUSIONS: We showed that in patients with antihistamine-resistant CU the addition of montelukast significantly diminished symptoms in only a small minority of patients. However, response to add-on montelukast was seen in the subgroup of patients with particularly severe disease. To confirm this observation, a study with a larger group of patients is warranted.
|
Authors | Mitja Kosnik, Tjasa Subic |
Journal | Respiratory medicine
(Respir Med)
Vol. 105 Suppl 1
Pg. S84-8
(Oct 2011)
ISSN: 1532-3064 [Electronic] England |
PMID | 22015095
(Publication Type: Controlled Clinical Trial, Journal Article)
|
Copyright | Copyright © 2011 Elsevier Ltd. All rights reserved. |
Chemical References |
- Acetates
- Cyclopropanes
- Histamine H1 Antagonists, Non-Sedating
- Quinolines
- Sulfides
- montelukast
|
Topics |
- Acetates
(administration & dosage, pharmacology)
- Chronic Disease
- Cross-Over Studies
- Cyclopropanes
- Double-Blind Method
- Female
- Histamine H1 Antagonists, Non-Sedating
(administration & dosage, pharmacology)
- Humans
- Male
- Middle Aged
- Quinolines
(administration & dosage, pharmacology)
- Sulfides
- Surveys and Questionnaires
- Treatment Outcome
- Urticaria
(drug therapy, immunology)
|